HR. 9661In Committee
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Summary not available yet.
Plain-English overview
What this bill does
A plain-English summary is not available for this bill yet.
Current status
Where it stands
Status
In Committee
Latest action
2026-07-14 — Referred to the House Committee on Energy and Commerce.
Related context
Topics and policy areas
undefined